- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- FDA approves first generic version of Genentech chemotherapy pill
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched its new chemotherapy drug.
Sagent sent that its paclitaxel injection USP is available in 30-mg, 100-mg and 300-mg latex-free, multi-dose vials. Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma, Sagent said.
"Paclitaxel is currently on the American Society of Health-System Pharmacists' and the U.S. [Food and Drug Administration] drug shortage lists and we are pleased to be able to help supply this vital chemotherapy option to patients," Sagent founder, board chairman and CEO Jeffrey Yordon said. "The launch of paclitaxel expands our rapidly growing portfolio of injectable oncolytics to six products."
U.S. market for generic injectable paclitaxel approximates $46 million, according to IMS Health data.